
(d) a C_{3-6} cycloalkyl group.

2. The compound according to claim 1, which is a~~A~~ compound represented by the following formula [I-a] or a pharmaceutically acceptable salt thereof:



[I-a]

wherein

R^1 is

(1) a hydrogen atom,

(2) a hydroxy group, or

(3) a C_{1-6} alkoxy group optionally substituted by C_{6-10} aryl group(s);

R^2 and R^3 are the same or different and each is

(1) a hydrogen atom, or

(2) a C_{1-6} alkyl group optionally substituted by 1 to 3 substituents selected from

(a) a hydroxy group, and

(b) a C_{1-6} alkoxy group;

$R^{7'}$ is a C_{1-6} alkyl group optionally substituted by 1 to 3 substituents selected from

(a) a hydroxy group,

(b) a C_{1-6} alkoxy group, and

(c) an amino group optionally mono- or di-substituted by C_{1-6} alkyl group(s), and

R^8 is

(1) a C_{1-6} alkyl group optionally substituted by 1 to 3 substituents selected from

(a) a hydroxy group,

(b) a C_{1-6} alkoxy group optionally substituted by C_{6-10} aryl group(s),

(c) a C_{3-6} cycloalkyl group optionally substituted by C_{1-6}

(c) a C_{3-6} cycloalkyl group optionally substituted by C_{1-6} alkoxy group(s),

(d) a C_{6-10} aryl group,

(e) a 5- or 6-membered unsaturated heterocyclic group optionally substituted by oxo group(s),

(f) a 5- to 8-membered saturated heterocyclic group optionally substituted by 1 to 3 substituents selected from

(i) a hydroxy group,

(ii) a C_{1-6} alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a C_{1-6} alkoxy group,

(iii) a C_{1-6} alkoxy group, and

(iv) an oxo group,

(g) a C_{3-6} cycloalkyloxy group,

(h) a C_{6-10} aryloxy group,

(i) a 5- or 6-membered unsaturated heterocyclyloxy group,

(j) a 5- or 6-membered saturated heterocyclyloxy group, and

(k) an amino group optionally mono- or di-substituted by substituents selected from

(i) a C_{1-6} alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group, a carboxy group and a carboxy-C_{1-6} alkoxy group,


(ii) a C_{1-6} alkyl-carbonyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a C_{1-6} alkoxy group,


(iii) a C_{1-6} alkoxy-carbonyl group optionally substituted by C_{6-10} aryl group(s), and


(iv) a C_{3-6} cycloalkyl-carbonyl group optionally substituted by C_{1-6} alkoxy group(s),


or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1, which is a~~A~~ compound selected from the following formulas











~~and~~




and



or a pharmaceutically acceptable salt thereof.


6. The compound according to claim 5, which is a compound of the following formula



or a pharmaceutically acceptable salt thereof.


7. The compound according to claim 5, which is a compound of

the following formula




or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 5, which is a compound of the following formula




or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 5, which is a compound of the following formula




or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 5, which is a compound of the following formula



or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 5, which is a compound of the following formula



or a pharmaceutically acceptable salt thereof.

~~6~~12. A pharmaceutical composition comprising the compound according to any one of claims 1 to ~~5~~11, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

~~7~~13. An ITK inhibitor comprising the compound according to any one of claims 1 to ~~5~~11, or a pharmaceutically acceptable salt thereof.

14. An ITK inhibitor comprising the compound according to claim 5, or a pharmaceutically acceptable salt thereof.

~~8~~15. An agent for the treatment or prophylaxis of an inflammatory disease, comprising the compound according to any one of claims 1 to ~~5~~11, or a pharmaceutically acceptable salt thereof.

~~9~~16. The agent according to claim ~~8~~15, wherein the inflammatory disease is rheumatoid arthritis.

~~10~~17. An agent for the treatment or prophylaxis of an allergic disease, comprising the compound according to any one of claims 1 to ~~5~~11, or a pharmaceutically acceptable salt thereof.

~~11~~18. An agent for the treatment or prophylaxis of an autoimmune disease, comprising the compound according to any one of claims 1 to ~~5~~11, or a pharmaceutically acceptable salt thereof.

~~12~~19. The agent according to claim ~~11~~18, wherein the autoimmune disease is rheumatoid arthritis.

~~13~~20. An inhibitor of rejection in transplantation, comprising the compound according to any one of claims 1 to ~~5~~11, or a pharmaceutically acceptable salt thereof.

21. An inhibitor of rejection in transplantation, comprising the compound according to claim 5, or a pharmaceutically acceptable salt thereof.

~~14. A method of inhibiting ITK in a mammal, comprising administering a pharmaceutically effective amount of the compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, to the mammal.~~

~~15. A method for treating or preventing an inflammatory disease in a mammal, comprising administering a pharmaceutically effective amount of the compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, to the mammal.~~

~~16. The method according to claim 15, wherein the inflammatory disease is rheumatoid arthritis.~~

~~17. A method for treating or preventing an allergic disease in a mammal, comprising administering a pharmaceutically~~

~~effective amount of the compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, to the mammal.~~

~~18. A method for treating or preventing an autoimmune disease to a mammal, comprising administering a pharmaceutically effective amount of the compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, to the mammal.~~

~~19. The method according to claim 18, wherein the autoimmune diseases is rheumatoid arthritis.~~

~~20. A method of suppressing rejection in transplantation in a mammal, comprising administering a pharmaceutically effective amount of the compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, to the mammal.~~

~~21~~22. Use of the compound according to any one of claims 1 to ~~5~~11, or a pharmaceutically acceptable salt thereof, for producing an agent for the treatment or prophylaxis of an inflammatory disease.

~~22~~23. The use according to claim ~~21~~22, wherein the inflammatory disease is rheumatoid arthritis.

~~23~~24. Use of the compound according to any one of claims 1 to ~~5~~11, or a pharmaceutically acceptable salt thereof, for producing an agent for the treatment or prophylaxis of an allergic disease.

~~24~~25. Use of the compound according to any one of claims 1 to ~~5~~11, or a pharmaceutically acceptable salt thereof, for producing an agent for the treatment or prophylaxis of an autoimmune disease.

~~25~~26. The use according to claim ~~24~~25, wherein the autoimmune diseases is rheumatoid arthritis.

~~26~~27. Use of the compound according to any one of claims 1 to ~~5~~11, or a pharmaceutically acceptable salt thereof, for producing an inhibitor of rejection in transplantation.